5-177515944-T-TCATC
Position:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_016222.4(DDX41):c.418_419insGATG(p.Asp140GlyfsTer2) variant causes a stop gained, frameshift change. The variant allele was found at a frequency of 0.000201 in 1,613,892 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00021 ( 0 hom. )
Consequence
DDX41
NM_016222.4 stop_gained, frameshift
NM_016222.4 stop_gained, frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.07
Genes affected
DDX41 (HGNC:18674): (DEAD-box helicase 41) DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure, such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. Based on their distribution patterns, some members of the DEAD box protein family are believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. The protein encoded by this gene is a member of the DEAD box protein family and interacts with several spliceosomal proteins. In addition, the encoded protein may recognize the bacterial second messengers cyclic di-GMP and cyclic di-AMP, resulting in the induction of genes involved in the innate immune response. [provided by RefSeq, Jan 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 5-177515944-T-TCATC is Pathogenic according to our data. Variant chr5-177515944-T-TCATC is described in ClinVar as [Likely_pathogenic]. Clinvar id is 210843.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DDX41 | NM_016222.4 | c.418_419insGATG | p.Asp140GlyfsTer2 | stop_gained, frameshift_variant | 5/17 | ENST00000330503.12 | NP_057306.2 | |
DDX41 | NM_001321732.2 | c.40_41insGATG | p.Asp14GlyfsTer2 | stop_gained, frameshift_variant | 4/16 | NP_001308661.1 | ||
DDX41 | NM_001321830.2 | c.40_41insGATG | p.Asp14GlyfsTer2 | stop_gained, frameshift_variant | 5/17 | NP_001308759.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DDX41 | ENST00000330503.12 | c.418_419insGATG | p.Asp140GlyfsTer2 | stop_gained, frameshift_variant | 5/17 | 1 | NM_016222.4 | ENSP00000330349 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000658 AC: 10AN: 152018Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
10
AN:
152018
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000875 AC: 22AN: 251444Hom.: 0 AF XY: 0.0000883 AC XY: 12AN XY: 135914
GnomAD3 exomes
AF:
AC:
22
AN:
251444
Hom.:
AF XY:
AC XY:
12
AN XY:
135914
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000215 AC: 314AN: 1461874Hom.: 0 Cov.: 32 AF XY: 0.000204 AC XY: 148AN XY: 727234
GnomAD4 exome
AF:
AC:
314
AN:
1461874
Hom.:
Cov.:
32
AF XY:
AC XY:
148
AN XY:
727234
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000658 AC: 10AN: 152018Hom.: 0 Cov.: 32 AF XY: 0.0000674 AC XY: 5AN XY: 74208
GnomAD4 genome
AF:
AC:
10
AN:
152018
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74208
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
DDX41-related hematologic malignancy predisposition syndrome Pathogenic:6Other:2
risk factor, no assertion criteria provided | literature only | OMIM | Mar 16, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jul 24, 2018 | The DDX41 c.415_418dupGATG p.(Asp140GlyfsTer2) causes a shift in the protein reading frame that is predicted to result in premature termination of the protein. Loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay is expected. This variant has been identified in individuals with a phenotype consistent with familial myeloproliferative/lymphoproliferative neoplasms (Polprasert et al. 2015; Lewinsohn et al. 2016). At least three individuals, ranging in age from 55 to 76 years, from these families also carried the variant but did not show signs of disease, though incomplete penetrance has been reported (Lewinsohn et al. 2016). The highest frequency of this allele in the Genome Aggregation Database is 0.000166 in the European (non-Finnish) population (version 2.1.1). Cheah et al. (2017) report that the c.415_418dupGATG variant is the most common DDX41 variant in Caucasian patients and suggest that it may be a founder variant in this population. Based on the available evidence, the c.415_418dupGATG p.(Asp140GlyfsTer2) variant is classified as likely pathogenic for susceptibility to multiple types of familial myeloproliferative/lymphoproliferative neoplasms. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 13, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 08, 2024 | Variant summary: DDX41 c.415_418dupGATG (p.Asp140GlyfsX2) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 8.7e-05 in 251444 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in DDX41 causing DDX41-Related Hematologic Malignancy Predisposition Syndrome, allowing no conclusion about variant significance. c.415_418dupGATG has been reported in the literature in individuals affected with DDX41-Related Hematologic Malignancy Predisposition Syndrome (examples: Lewinsohn_2016 and Dalle_2020). These data indicate that the variant is likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 26712909, 31400013). ClinVar contains an entry for this variant (Variation ID: 210843). Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided, no classification provided | literature only | GeneReviews | - | Common recurrent germline variant, esp in persons of European ancestry [Polprasert et al 2015, Cheah et al 2017, Quesada et al 2019, Bannon et al 2021] - |
Pathogenic, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Jun 08, 2022 | The DDX41 c.415_418dup (p.Asp140GlyfsTer2) change causes a frameshift and the creation of a premature stop codon. This change is predicted to cause protein truncation or absence of the protein due to nonsense-mediated decay. This variant has been reported in individuals with a personal and/or family history of acute myeloid leukemia and/or myelodysplastic syndrome (PMID: 25920683, 30963592, 31400013, 31484648, 33585199). This variant has a maximum subpopulation frequency of 0.017% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). In summary, this variant meets criteria to be classified as pathogenic for familial myeloproliferative/lymphoproliferative neoplasms. - |
Pathogenic, criteria provided, single submitter | research | HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology | May 12, 2016 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genomics Labs, University Health Network | Feb 17, 2022 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change creates a premature translational stop signal (p.Asp140Glyfs*2) in the DDX41 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DDX41 are known to be pathogenic (PMID: 26712909, 27133828). This variant is present in population databases (rs762890562, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with acute myeloid leukemia or myelodysplastic syndrome (PMID: 25920683, 30963592). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 210843). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 17, 2022 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 26944477, 29372845, 26940275, 25920683, 26712909, 30963592, 31484648, 31400013, 27819178, 28637623, 28955657, 29790872, 26917736, 33778416, 33850299, 33585199) - |
DDX41-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 28, 2024 | The DDX41 c.415_418dupGATG variant is predicted to result in a frameshift and premature protein termination (p.Asp140Glyfs*2). This variant has been reported to be causative for myelodysplastic syndrome and acute myeloid leukemia (for example, see: Polprasert et al. 2015. PubMed ID: 25920683; Lewinsohn et al. 2016. PubMed ID: 26712909). This variant is reported in 0.017% of alleles in individuals of European (Non-Finnish) descent in gnomAD and is interpreted as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/210843/). Frameshift variants in DDX41 are expected to be pathogenic. Taken together, this variant is interpreted as pathogenic. - |
Acute myeloid leukemia Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Oct 01, 2021 | DNA sequence analysis of the DDX41 gene demonstrated a four base pair deletion in exon 5, c.415_418dup. This pathogenic sequence change results in an amino acid frameshift and creates a premature stop codon at position 2 in the new reading frame, p.Asp140Glyfs*2. This pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated DDX41 protein with potentially abnormal function. This sequence change has been described in the gnomAD database with a frequency of 0.017% in the European (non-Finnish) subpopulation. This pathogenic sequence change is a well described, recurrent variant that has previously been described in multiple individuals with DDX41-related myeloid malignancies (PMID: 25920683, 31484648, 26712909, 31400013, 30963592). This pathogenic sequence change is the most likely cause of this patient's phenotype. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at